Champions Oncology reported Q1 fiscal 2027 revenue of $15.23 million, up 8.8% year-over-year, driven by stronger execution in its core research services and increased data licensing revenue. Adjusted earnings per share beat estimates at $0.05 versus a $0.01 loss expected, while adjusted EBITDA rose significantly to $671,000 from $59,000, reflecting improved margins. Despite a GAAP net loss of $426,000, the company ended the quarter with $4.36 million in cash and no debt. The results indicate operational improvements, though adjusted EBITDA should not be seen as cash flow, which was negative due to working capital changes.
TIA cryptocurrency rose sharply by 9.1% to $0.7265 despite a 3.5% drop in the overall crypto market cap to $2.76 trillion. This gain contrasts with declines in other altcoins like ZRO and PYTH, highlighting TIA's resilience driven by a recent data-av...
US spot Ether ETFs experienced net outflows of about $320 million in the week ending October 16, 2026, surpassing the $228 million outflows from spot Bitcoin ETFs during the same period. The largest withdrawals came from BlackRock’s iShares Ethereum ...
Over the past 90 days, the market value of stablecoins on the Cardano blockchain increased by 25.8%, reaching $68.3 million. The largest share of this total is USD Coin (USDC) at $44.4 million, followed by USDM at $13.5 million and RealFi's USDrf at ...
Blue Bird has updated its FY2026 adjusted EBITDA guidance to a narrower range of $245-250 million, with previous estimates at the lower end of this range. The company has consistently outperformed its guidance for fifteen consecutive quarters, demons...
Ethereum plans to activate the Hoodi testnet for its Glamsterdam upgrade on October 26, increasing the gas limit to 200 million to enhance testing. This follows the Sepolia testnet fork on October 6, which was an earlier step in the rollout. Glamster...
